For years, obesity rates in the US have gone in one direction: up. From the first year it was launched, Gallup’s National ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

A new Gallup poll indicates that the obesity rate among U.S. adults has declined over the past three years as the number of ...

The GLP-1 drugs, produced by Novo Nordisk and Eli Lilly, have been credited with helping weight-loss, preventing diabetes and other positive effects.

The Gallup National Health and Well-Being Index shows that GLP-1 weight loss drugs are having an effect: The U.S. obesity ...

The same survey also found that weight loss drugs such as Ozempic and Wegovy – known as GLP-1 ( glucagon-like peptide-1) ...

This article was reviewed by Darragh O’Carroll, MD. Ozempic Alternatives for Weight Loss Key takeaways: Ozempic® alternatives ...

Pfizer CEO Albert Bourla called Novo Nordisk's bid for obesity drug developer Metsera an "illegal...end-run around antitrust laws." ...

The menopausal transition is a pivotal time in women’s health, bringing about profound hormonal, metabolic and physiologic ...

GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in ...

This article was reviewed by Lynn Marie Morski, MD, JD. Ozempic Stomach Paralysis: Risks & Treatments Key takeaways: Stomach ...

Many doctors and patients came to believe the rise in obesity may be all but biologically inescapable, despite the grave ...